Physician
Hematology
Dr. Ian W. Flinn, MD
|
|
Give Review
Flinn is an expert in the field of Hematology. He attended Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. He over the years received 3 awards: "America's Top Doctors", "Nashville Lifestyles Magazine" and "America's Top Doctors for Cancer". Doctor Ian W. Flinn, MD is a published MD. He has 62 publications published. The most current publication "Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial." Flinn is registered with Medicare and accepts Medicare payments.
Publications
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
- Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
- Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludara...
- The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
- Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.
- Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
- Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
- A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituxim...
- A phase I trial of the Fc engineered CD19 antibody XmAb®5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic leukemia.
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma.
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non...
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma.
- Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
- Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
- Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL).
- Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study.
- Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma.
- Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.
- PI3Kdelta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.
- A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIRTM Therapeutic Protein in Chronic Lymphocytic Leuke...
- Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
- Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
- GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia.
- CD37: the comeback kid.
- B-cell receptor inhibitors in chronic lymphocytic leukemia.
- Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup...
- Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
- Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
- Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.
- Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
- Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
- Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell ly...
- Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III T...
- Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial...
- Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
- Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
- Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
- Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma.
- Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
- High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
- FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
- Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
- ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
- Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
- Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors.
- Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
- Incorporating monoclonal antibodies in blood and marrow transplantation.
- MALT Lymphomas.
- Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
- Chronic lymphocytic leukemia: advances in biology and therapeutics.
- Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
- Lymphoma therapy: the challenges ahead.
- Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
- Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
- The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
- Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Nashville Lifestyles Magazine
- America's Top Doctors for Cancer
Education
-
Johns Hopkins University -
University of Michigan Hospitals and Health Centers -
Johns Hopkins University School of Medicine
Drug Facts
| NPI NUMBER | 1417990367 | |
| NPPES Provider LastName | FLINN | |
| NPPES Provider FirstName | IAN | |
| NPPES Provider ZIPCode | 372031632 | |
| NPPES Provider State | TN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 700.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 31.0 | |
| Percent Opioid Claims | 4.43 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417990367 |
| Last Name Of The Provider | FLINN |
| First Name Of The Provider | IAN |
| View All |
Similar Doctors
|
Catherine Lucid, APRN |
|
|
Dr. Madan Jagasia, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Vicki L. Keedy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin K. Ancell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Greer, MD |
|
Dr. Jeffery F. Patton, MD |
|
|
Dr. James P. Elrod, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Utpal Dave, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John D. Hainsworth, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Philip E. Lammers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jia Bi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Habib H. Doss, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jesus G. Berdeja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laquisa C. Hill, MD |
|
|
Dr. Melissa L. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Hava Fife, APRN |
|
|
Ojiugo M. Iko, MB
This Doctor is OpenDoctor Recommended.
|